DEERFIELD, Ill.--(BUSINESS WIRE)--The National Organization for Rare Disorders (NORD) honored Lundbeck Inc. last night with its 2010 Corporate Award for the development of Sabril® (vigabatrin) Powder for Oral Solution. Presented at NORD’s Partners in Progress Gala in Washington D.C., the award recognizes efforts put forth by Lundbeck to make Sabril available in the U.S. for the treatment of infantile spasms (IS), a rare and difficult-to-treat epilepsy syndrome that usually strikes infants between four to eight months old.1
